Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
Kawanami D, Takashi Y, Muta Y, Oda N, Nagata D, Takahashi H, Tanabe M. Kawanami D, et al. Front Pharmacol. 2021 Oct 28;12:754239. doi: 10.3389/fphar.2021.754239. eCollection 2021. Front Pharmacol. 2021. PMID: 34790127 Free PMC article. Review.
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, Horikawa T, Fujimura-Tanaka Y, Hamanoue N, Motonaga R, Tanabe M, Inoue R, Yanase T, Kawanami D. Komatsu S, et al. Among authors: kawanami t, kawanami d. Endocr J. 2020 Jan 28;67(1):99-106. doi: 10.1507/endocrj.EJ19-0428. Epub 2019 Nov 27. Endocr J. 2020. PMID: 31776304 Free article.
Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Shigeoka T, Nomiyama T, Kawanami T, Hamaguchi Y, Horikawa T, Tanaka T, Irie S, Motonaga R, Hamanoue N, Tanabe M, Nabeshima K, Tanaka M, Yanase T, Kawanami D. Shigeoka T, et al. Among authors: kawanami t, kawanami d. J Diabetes Investig. 2020 Sep;11(5):1137-1149. doi: 10.1111/jdi.13247. Epub 2020 Apr 9. J Diabetes Investig. 2020. PMID: 32146725 Free PMC article.
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D; Collaborators in the Repaglinide Glucose Oscillation Study in Fukuoka (REGO-F) trial. Terawaki Y, et al. Among authors: kawanami d. Diabetol Int. 2020 Feb 14;11(3):274-282. doi: 10.1007/s13340-020-00426-w. eCollection 2020 Jul. Diabetol Int. 2020. PMID: 32802709 Free PMC article.
ROCK Inhibition May Stop Diabetic Kidney Disease.
Matoba K, Takeda Y, Nagai Y, Kanazawa Y, Kawanami D, Yokota T, Utsunomiya K, Nishimura R. Matoba K, et al. Among authors: kawanami d. JMA J. 2020 Jul 15;3(3):154-163. doi: 10.31662/jmaj.2020-0014. Epub 2020 Jun 19. JMA J. 2020. PMID: 33150249 Free PMC article. Review.
Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet.
Horikawa T, Kawanami T, Hamaguchi Y, Tanaka Y, Kita S, Ryorin R, Takashi Y, Takahashi H, Tanabe M, Yanase T, Kawanami D, Nomiyama T. Horikawa T, et al. Among authors: kawanami t, kawanami d. Heliyon. 2020 Nov 6;6(11):e05431. doi: 10.1016/j.heliyon.2020.e05431. eCollection 2020 Nov. Heliyon. 2020. PMID: 33204884 Free PMC article.
81 results